Literature DB >> 10084754

Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection.

M D Denton1, R M Reul, V R Dharnidharka, J C Fang, P Ganz, D M Briscoe.   

Abstract

Major advances have been made in understanding the expression and function of CD40 and its ligand CD154. It is now clear that CD40/CD154 interactions are critical in many aspects of the immune response, including T cell activation, T cell-dependent macrophage activation, T cell-B cell interactions and endothelial activation. Moreover, increasing evidence supports a central role for CD40/CD154 interactions in the immune processes of allograft rejection. Functional studies using blocking monoclonal antibodies have revealed beneficial effects of interupting CD40/CD154 co-stimulation in animal models of transplantation, particularly in association with interuption of the CD28/B7 pathway. A next step is to develop new therapeutic approaches to interrupting this pathway in humans, either through the development of receptor antagonists or through the understanding of intracellular signaling pathways utilized by these molecules.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10084754

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

1.  Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Authors:  G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

Review 2.  Essential concept of transplant immunology for clinical practice.

Authors:  Damodar Kumbala; Rubin Zhang
Journal:  World J Transplant       Date:  2013-12-24

3.  Proinflammatory functions of vascular endothelial growth factor in alloimmunity.

Authors:  Marlies E J Reinders; Masayuki Sho; Atsushi Izawa; Ping Wang; Debabrata Mukhopadhyay; Kerith E Koss; Christopher S Geehan; Andrew D Luster; Mohamed H Sayegh; David M Briscoe
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.